AVA 6000
Alternative Names: AVA-6000; AVA6000 pro-Doxorubicin; FAP Pro-doxorubicinLatest Information Update: 06 Jun 2025
At a glance
- Originator Tufts University School of Medicine
- Developer Avacta
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Peptide drug conjugates; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacokinetics data from a phase I trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Pharmacokinetics data from a preclinical study in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 07 Mar 2025 Efficacy data from a phase I trial in Solid tumors released by Avacta